Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP306 in hyperphosphatemia on maintenance hemodialysis (Phase 2b)
ChiCTR2600126231Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EOS789 in hyperphosphatemia (7 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in serum phosphorus from baseline to end of treatment or specified stopping points. Started Jun 2026; status: recruiting.
02
Drugs
EOS789
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on ChiCTR2600126231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126231.